Clinical Trial Update: A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study update for BIND-014, a docetaxel nanoparticle formulation, in second-line non-small cell lung cancer (KRAS-positive and squamous cell subtypes); t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• BIND-014 (docetaxel nanoparticle)

Snippet

Sponsor: BIND Therapeutics | Conditions: KRAS Positive Patients With Non-small Cell Lung Cancer, Squamous Cell Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED